references
FINANCIAL REPORT
3 STOCKS OF DRUGS
In 2015, DNDi purchased vials of SSG, lipossomal amphotericin B (Ambisome®), paromomycin, and caps of miltefosine 10mg and 50mg at an estimated value of EUR 154,357 from various partners (MSF Logistique, MSF supply, IDA Foundation), for use in the routine VL patient management and on-going VL clinical trials (HIV/VL 2014 Countries / drugs India Ethiopia Kenya Sudan Uganda Total vials/caps Total in EUR 500 1,070 1,000 650 3,220 22,540 SSG (1) Quantity Vials Paromomycin AmBisome® (2) 2,895 1,839 128 160 140 5,162,00 72,268 13,050 3,000 4,060 930 1,100 22,140 22,140 co-infection study and Miltefosine Allometric Study). Stocks of SSG, AmBisome®, miltefosine, and paromomycin at an estimated value of EUR 156,537 are stored at clinical trial sites in Ethiopia, Kenya, Sudan, and Uganda.The stock held in India in 2014 was donated to the Indian Ministry of Health in 2015. Quantity Caps Miltefosine 50mg 15,894 2,300 18,194 18,194 Miltefosine 10mg 38,022 38,022 38,022 173,164 Total in EUR 107,496 34,546 13,342 10,170 7,610
(1) SSG Cost per vial = EUR 7; (2) AmBisome® Cost per vial = EUR 14; paromomycin & miltefosine are valued at EUR 1 per unit
2015 Countries / drugs India Ethiopia Kenya Sudan Uganda Total vials/caps Total in EUR 4,367 4,769 1,825 800 11,761 70,566
®
Quantity Vials Paromomycin SSG (1) AmBisome® (2) 555 1,726 835 541 3,657 65,826 2,150 4,620 2,105 700 9,575 9,575
Quantity Caps Miltefosine 50mg 3,150 840 3,990 3,990 Miltefosine 10mg 3,822 2,758 6,580 6,580 Total in EUR 38,342 71,274 28,085 18,836 156,537
(1) SSG Cost per vial = EUR 6; (2) AmBisome Cost per vial = EUR 18; paromomycin & miltefosine are valued at EUR 1 per unit
76 › DNDi Annual Report 2015